Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
A home care provider has launched a new fleet of hybrid cars. Care 24-7 said the move will allow its teams to reach clients across Yorkshire and the North East more efficiently and with a reduced ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...
In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...
A study reveals that sleep aids like Ambien, containing zolpidem, may hinder the brain's waste-clearing process during deep sleep, increasing the risk of Alzheimer’s disease. The drug disrupts ...